Dr. Kim Branson is a world-renowned expert in artificial intelligence and machine learning. With over 20 years of experience in the industry, he leads a large team of ML researchers and engineers at GSK who focus on the application of AI to drug discovery and development. Dr. Branson's expertise lies in modelling and machine learning for drug and vaccine discovery, combining perspectives from academia to technology start-up. His leadership has helped GSK build one of the industry's most successful in-house AI departments, which leverages the potential of complex genetic data to maximise GSK's industry-leading collaborations.

Prior to joining GSK, Dr. Branson was the Head of AI, Early Clinical Development at Genentech. He has also been involved in various large-scale machine learning and medical informatics initiatives, ranging from computational drug design to disease risk prediction. This work is vital to translational research, which aims to bridge the gap between basic science and clinical practice. By leveraging the potential of complex genetic data through AI and ML, GSK is able to accelerate the translation of scientific knowledge into new drugs and therapies for patients.